Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 18;7(12):e70275.
doi: 10.1002/hsr2.70275. eCollection 2024 Dec.

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Ping-Feng Wu  1   2   3 , Hsi-Hsun Lin  3   4 , Hsin-Pai Chen  1   2 , Po-Chieh Huang  1 , Meng-Yu Ke  1
Affiliations

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Ping-Feng Wu et al. Health Sci Rep. .

Abstract

Background and aims: People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)-associated negative metabolic consequences. We aimed to investigate the metabolic outcomes of PLWH by replacing rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) with RPV/tenofovir alafenamide (TAF)/FTC.

Methods: This retrospective study enrolled PLWH who changed from RPV/TDF/FTC to RPV/TAF/FTC between January 2019 and September 2023. Metabolic profiles were compared 1 year before and 3 years after changing cART using Cochran's Q and one-way ANOVA. The independent risk factors for metabolic syndrome were analyzed using logistic regression.

Results: A total of 182 patients were enrolled. The prevalence of metabolic syndrome has increased from 28% to 40.7%. The prevalence of hypertension and abnormal lipid levels significantly increased in the first year after changing cART, but the prescription of medicine for dyslipidemia increased in the second year (p = 0.025) and that for hypertension increased in the third year (p < 0.001). In addition to the criteria, body mass index (BMI) before changing cART was the only predictor of metabolic syndrome in the third year (OR 1.36; 95% CI 1.19-1.55; p < 0.001). The prevalence of metabolic syndrome and BMI did not increase significantly during the second and third years.

Conclusions: A gradually higher prevalence of metabolic syndrome among PLWH occurred with changes from RPV/TDF/FTC to RPV/TAF/FTC but plateaued beyond 2 years. However, fewer drugs for dyslipidemia, diabetes, and hypertension were prescribed within the first year after changing cART.

Keywords: HIV; lipids; metabolic syndrome; tenofovir alafenamide; tenofovir disoproxil fumarate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Teeraananchai S., Kerr S., Amin J., Ruxrungtham K., and Law M., “Life Expectancy of HIV‐Positive People After Starting Combination Antiretroviral Therapy: A Meta‐Analysis,” HIV Medicine 18, no. 4 (2017): 256–266. - PubMed
    1. Antiretroviral Therapy Cohort Collaboration . “Survival of HIV‐Positive Patients Starting Antiretroviral Therapy Between 1996 and 2013: A Collaborative Analysis of Cohort Studies,” Lancet HIV 4, no. 8 (2017): e349–e356. - PMC - PubMed
    1. Alberti K. G., Eckel R. H., Grundy S. M., et al., “Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” Circulation 120, no. 16 (2009): 1640–1645. - PubMed
    1. Nguyen K. A., Peer N., Mills E. J., and Kengne A. P., “A Meta‐Analysis of the Metabolic Syndrome Prevalence in the Global HIV‐Infected Population,” PLoS One 11, no. 3 (2016): e0150970. - PMC - PubMed
    1. Todowede O. O., Mianda S. Z., and Sartorius B., “Prevalence of Metabolic Syndrome Among HIV‐Positive and HIV‐Negative Populations in Sub‐Saharan Africa—A Systematic Review and Meta‐Analysis,” Systematic Reviews 8, no. 1 (2019): 4. - PMC - PubMed

LinkOut - more resources